BHVN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Stats
Today's Volume	587 967
Average Volume	1.43M
Market Cap	3.39B
EPS	$0 ( 2024-05-10 )
Next earnings date	( $-1.680 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.57
ATR14	$0.0650 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-13	Bailey Gregory	Buy	15 000	Common Shares
2024-05-13	Childs John W	Buy	28 500	Common Shares
2024-04-30	Mehta Kishan	Buy	16 592	Stock Option (Right to Buy)
2024-04-30	Heffernan Michael Thomas	Buy	16 592	Stock Option (Right to Buy)
2024-04-30	Gregory Julia P	Buy	16 592	Stock Option (Right to Buy)

INSIDER POWER
97.08
Last 99 transactions
Buy: 15 095 606 \| Sell: 259 097

Volume Correlation

Long: 0.55 (weak)

Short: -0.71 (moderate negative)

Signal:(51.306) Neutral

Biohaven Pharmaceutical Correlation

10 Most Positive Correlations
THD	0.906
KB	0.888
PFGC	0.887
BMEZ	0.884
SHG	0.882
NUVB	0.877
HD	0.872
BKF	0.871
PSA-PN	0.871
USB-PQ	0.868

10 Most Negative Correlations
CMO	-0.872
EMTY	-0.868
CSLT	-0.808
DEF	-0.808
LABD	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biohaven Pharmaceutical Correlation - Currency/Commodity

-0.73
( moderate negative )

-0.50
( weak negative )

0.00
( neutral )

-0.33
( neutral )

0.81
( strong )

0.38
( neutral )

Biohaven Pharmaceutical Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.37M (0.00 %)
EPS:	$-5.73

FY	2023
Revenue:	$0
Gross Profit:	$-3.37M (0.00 %)
EPS:	$-5.73

FY	2022
Revenue:	$0
Gross Profit:	$-1.39M (0.00 %)
EPS:	$-12.75

Financial Reports:

No articles found.

Biohaven Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.